Physician profile
Malek S Karassi
NPI 1447273586
$13,508.39
in general payments reported to CMS, 2019-2025
38 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,373 · 2020: $2,505 · 2021: $2,111 · 2022: $1,738 · 2023: $1,664 · 2024: $1,272 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,739 · Education: $41.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,739.25 |
| Education | $41.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,649.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,469.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $1,385.66 | 2019-2025 | Freestyle Libre, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,265.29 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Sanofi-Aventis U.S. LLC | $1,237.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,157.49 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $630.59 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $599.99 | 2021-2025 | Minimed 780g |
| Corcept Therapeutics | $535.37 | 2019-2025 | Korlym |
| Merck Sharp & Dohme LLC | $476.98 | 2019-2021 | |
| Dexcom, INC. | $441.51 | 2021-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $339.51 | 2019-2025 | |
| Ibsa Pharma INC. | $282.35 | 2019-2024 | Tirosint, Licart |
| Abbvie INC. | $270.60 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $253.25 | 2021-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $224.93 | 2019-2025 | Repatha, Tepezza, Repatha |
| Tandem Diabetes Care, INC. | $174.67 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $161.73 | 2024-2025 | Qutenza |
| Medtronic Minimed, INC. | $144.36 | 2020 | |
| Beta Bionics, INC. | $121.58 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Antares Pharma, INC. | $120.74 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Insulet Corporation | $113.65 | 2022-2025 | Omnipod |
| Shire North American Group INC | $59.00 | 2019 | |
| Ascensia Diabetes Care US INC. | $53.70 | 2019-2020 | |
| Lifescan, INC. | $53.41 | 2020-2021 | |
| Amarin Pharma, INC. | $40.81 | 2019-2020 | |
| Tolmar, INC. | $30.83 | 2024-2025 | Jatenzo |
| Glaxosmithkline, LLC. | $26.73 | 2025 | Arexvy, Shingrix |
| Nevro Corp. | $26.03 | 2021 | |
| Horizon Therapeutics Plc | $25.61 | 2020-2021 | |
| Halozyme INC | $21.52 | 2023 | |
| Radius Health, INC. | $20.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.98 | 2020 | |
| Becton, Dickinson and Company | $18.56 | 2021 | |
| Embecta Corp. | $16.49 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Sequel Med Tech, LLC | $14.58 | 2025 | Twiist |
| Sun Pharmaceutical Industries INC. | $12.36 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malek Karassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.